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members, in a position that enhances and complements the vital
role of “cognitive, electrician, or plumber” HF cardiologists.
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Echocardiographic Findings in
Patients With Arrhythmogenic Right
Ventricular Cardiomyopathy/Dysplasia
We read with interest the study by Yoerger et al. (1) presenting
echocardiographic data of 29 probands affected by arrhythmogenic
right ventricular cardiomyopathy (ARVC) diagnosed with the
International Society and Federation of Cardiology task force
criteria. In all cases the echocardiogram showed typical features of
the disease. It is well known that ARVC diagnosis is made
considering different parameters. The purpose of their study was to
assess echocardiographic abnormalities in a series of patients
affected by ARVC, in whom the echocardiogram has not been
considered for the diagnosis.
Thus, we can assume that all these patients showed a clear form
of the disease, fulfilling the diagnostic criteria even in the absence
of the echocardiographic tool. However, the real problem is to
understand whether the typical ARVC echocardiographic alter-
ations have a diagnostic value per se, even when the task force
criteria (2 major, 1 major plus 2 minor, 4 minor) are not satisfied.
This point is critical because in the presymptomatic phase of the
disease the lack of diagnosis can lead to heavy consequences for the
subjects, who could be at risk of life-threatening ventricular
arrhythmias and sudden death.
Moreover, genetic studies (2) demonstrated that mutation
carriers often do not fulfill the published criteria. This leads to the
need to reevaluate the present task force criteria and to reexamine
the different echocardiographic abnormalities, trying to assess
which of these are specific to make a diagnosis of ARVC in the
absence of other codified criteria.
As shown by the investigators, a correct echocardiographic
evaluation can lead to the detection of several morphologic and
kinetic aspects of the right ventricle. At this point, considering that
an echocardiogram is a noninvasive technique that can be repeated
in time, can we consider this diagnostic tool as the “gold standard”
of ARVC diagnosis in asymptomatic patients or in patients with
minor forms of the disease (3)? Hence, the real significance of
echocardiographic abnormalities in this group of “uncertain sub-
jects” constitutes the major challenge in echocardiographic evalu-
tion of ARVC.
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Dr. Bauce and colleagues raise several issues with regard to our
investigation of the echocardiographic findings in arrhythmogenic
right ventricular dysplasia (ARVD). The first is to indicate that our
patients all met the task force criteria for ARVD/C without the
echocardiographic-derived data. Therefore, the diagnosis was ob-
vious without the data. This was an intrinsic design of our study
(1), as one cannot assess the utility of a diagnostic method without
having a firm diagnosis of the disease excluding the test that is
being evaluated because there is no “gold standard.”
The purpose of our report was to identify the best quantitative
echocardiographic markers of ARVD in individuals meeting task
force criteria for ARVD (2). The data presented compare the
measurements of different right ventricular (RV) dimensions in
ARVD probands versus controls. We found that the right ventricular
outflow tract was the most commonly enlarged dimension in ARVD
probands. We provided a numerical value that separated the two
groups. At present, it is not uncommon for echocardiographic
laboratories to report only qualitative RV size. In order to discriminate
the normal RV from the abnormal, as is required in the assessment for
ARVD, quantitative measurements should be used.
Additionally, Dr. Bauce and colleagues correctly point out the
difficulty detecting ARVD in its preclinical or “presymptomatic”
phase. We agree that there is an important need to be able to
detect minimal structural abnormalities of the RV in patients
suspected of ARVD. Upon its completion, the Multidisciplinary
Registry of ARVD will have quantitative data from echocardio-
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grams on a well-characterized population of probands meeting
ARVD task force criteria and their family members. It is our hope
that with these data, the diagnostic utility of these abnormal
echocardiographic parameters found in the probands can be tested
in family members at risk for ARVD who are asymptomatic and
do not yet meet full task force diagnostic criteria.
Currently, there remains no single defined “gold standard” test for
ARVD whether symptomatic or asymptomatic, but given its nonin-
vasive nature and ease of repeated performance, even in the presence
of implantable cardiovascular-defibrillators, transthoracic echocardi-
ography is a reasonable tool to study progression of this disease.
*Danita M. Yoerger, MD, MMSc
Hugh Calkins, MD
Frank Marcus, MD
Michael H. Picard, MD
*Cardiac Ultrasound Laboratory
Cardiology Division
Massachusetts General Hospital
YAW 5
55 Fruit Street
Boston, MA 02114
E-mail: dyoerger@partners.org
doi:10.1016/j.jacc.2005.08.018
REFERENCES
1. Marcus F, Towbin JA, Zareba W, et al. Arrhythmogenic right
ventricular dysplasia/cardiomyopathy (ARVD/C): a multidisciplinary
study: design and protocol. Circulation 2003;107:2975–8.
2. Yoerger DM, Marcus F, Sherrill D, et al., for the Multidisciplinary
Study of Right Ventricular Dysplasia. Echocardiographic findings in
patients meeting task force criteria for arrhythmogenic right ventricular
dysplasia: new insights from the Multidisciplinary Study of Right
Ventricular Dysplasia. J Am Coll Cardiol 2005;45:860–5.
Safety of Dobutamine
Contrast Stress Echocardiography
We agree with Tsutsui et al. (1) that dobutamine real-time
contrast echocardiography is both a safe and feasible technique.
Sonovue (Bracco Imaging, Milan, Italy) is commonly used in
Europe for left ventricular opacification, although it is not ap-
proved by the U.S. Food and Drug Administration (2). In Europe,
the summary of product characteristics of Sonovue was changed
following safety concerns in patients with significant coronary
artery disease (CAD). We have previously published similar
findings to those of Tsutsui et al. (3) from our experience using
both Sonovue and Optison during dobutamine stress echocardi-
ography in over 400 patients and low mechanical index real-time
imaging. Specifically, we found no increased incidence of arrhyth-
mia, ectopy, hypotension, or other side effects, and once again no
mortality or myocardial infarctions.
The data from Tsutsui et al. (1) and also our center should reassure
echocardiographers of the safety of contrast agents during dobutamine
stress. It is also important to remember that up to 30% of echocar-
diograms may be nondiagnostic owing to poor image quality, and
there are implications for both false positive and false negative results.
A false negative result may lead to false reassurance to a patient with
significant CAD, whereas a false positive test or nondiagnostic test
may lead to further noninvasive or invasive imaging. Other noninva-
sive tests are not without small but definite risks. The mortality from
single-photon emission computed tomography is reported at 0.05%
(4), and the mortality from coronary angiography is 0.03% to 0.26%
(5) as well as other peripheral vascular and cerebrovascular morbidi-
ties. It is therefore important that image quality during dobutamine
stress echocardiography is not sacrificed and the use of contrast
appears safe, feasible, and effective.
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We thank Mr. Timperley and Dr. Becher for their comments
regarding the safety of contrast echocardiography (1). Their findings
reinforce our results demonstrating no increase in the incidence of
adverse effects when using intravenous (IV) second-generation con-
trast agents and low mechanical index real-time imaging during
dobutamine stress echocardiography. Nevertheless, we would like to
emphasize that in our study (1), IV contrast agents were also used for
the assessment of myocardial perfusion.We tested two contrast agents
already approved by the Food and Drug Administration using the
same doses as recommended for the enhancement of left ventricular
opacification during stress testing (2). The high sensitivity of the low
mechanical index pulse scheme techniques for detecting small
amounts of microbubbles in the myocardium allowed for simulta-
neous evaluation of both contrast-enhanced wall motion and myo-
cardial perfusion with high feasibility and good safety profile. Con-
sistent with previous studies (3,4), we demonstrated that the analysis
of myocardial perfusion increased the sensitivity and diagnostic
accuracy of dobutamine stress echocardiography for detecting angio-
graphically significant coronary artery disease. Thus, our findings
demonstrate the potential use of real-time myocardial contrast echo-
cardiography as an alternative and safe method of perfusion imaging
during stress testing.
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